ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1387

Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab

Jeffrey Curtis1, Daniel Aletaha 2, Gerd Burmester 3, Kerri Ford 4, Hubert van Hoogstraten 5, Henry Leher 6, Karthinathan Thangavelu 7 and Vivian Bykerk 8, 1University of Alabama at Birmingham, Birmingham, AL, 2Medical University of Vienna, Vienna, Austria, 3Charité—University Medicine Berlin, Berlin, Germany, 4Sanofi Genzyme, Bridgewater, NJ, 5Sanofi, Bridgewater, NJ, 6Regeneron Pharmaceuticals, Inc, Tarrytown, NY, 7Sanofi Genzyme, Boston, MA, 8Hospital for Special Surgery, New York City, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: IL-6, outcomes and patient outcomes, Rheumatoid arthritis (RA), rheumatoid arthritis treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may decline treatment changes for fear of clinical worsening and losing the response they had so far achieved. Little is known about the likelihood of worsening after switching therapy to a drug with a different mechanism of action, and this limits patients’ ability to make informed decisions. We performed a post hoc analysis to assess the effect of switching from adalimumab to sarilumab in patients with RA who partially responded to adalimumab in MONARCH (NCT02332590), a head-to-head study of sarilumab versus adalimumab monotherapy. At the end of the trial, patients on adalimumab were switched to sarilumab 200 mg q2w for the open-label extension (OLE).

Methods: Thresholds of change in Clinical Disease Activity Index (CDAI) of ±6 and ±12 units were used to define meaningful improvement/worsening, anchored at the OLE baseline (BL). Partial responders to adalimumab or sarilumab were characterized at OLE BL and defined as having had a clinically meaningful change in CDAI (≤−12 if MONARCH BL CDAI >22 or ≤−6 if MONARCH BL CDAI >10 to ≤22) during MONARCH while still having moderate-to-high disease activity (CDAI >10) at OLE BL. Response was assessed by change in CDAI from OLE BL at Week 24. The proportions of partial responders achieving meaningful improvement or worsening were calculated.

Results: There were 369 patients enrolled in MONARCH, of whom 320 (87%) entered OLE—155 switching from adalimumab to sarilumab, 165 continuing sarilumab. Of the patients in OLE, 52% were partial responders at OLE BL: switch, n=91/155 (59%); continuation, n=74/165 (45%). Mean (SE) CDAI at OLE BL was 19.56 (0.86) in switch partial responders and 18.99 (1.02) in continuation partial responders, with mean (SE) change in CDAI from OLE BL at Week 24 of −7.37 (1.10) and −5.52 (0.94), respectively (Table). Based on a CDAI threshold of ±6, improvement in disease activity was observed in 57% (switch) and 43% (continuation), while worsening was observed in 6% and 4% of patients. No change (−6 to +6) was evident in 37% (switch) and 53% (continuation). Based on a CDAI threshold of ±12, improvement in disease activity was observed in 27% (switch) and 17% (continuation), while worsening was observed in 2% and 1%, and no change (−12 to +12) was evident in 71% and 81%, respectively. Other efficacy measures demonstrated improvements from baseline (Table). No new safety signals emerged during OLE, and the adverse event profile among switch patients was similar to that of continuation patients.

Conclusion: Among adalimumab partial responders who switched to sarilumab, there was a low (6%) likelihood of clinical worsening, and almost all patients (94%) experienced clinical improvement or had no change. These findings can help inform patients’ and clinicians’ shared decision making when considering changes in RA therapy.

Table. Summary of efficacy endpoints among CDAI partial responders*


Disclosure: J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; D. Aletaha, AbbVie, 2, 5, 8, AbbVie, Janssen, Lilly, Novartis, Pfizer, and Roche, 5, AbbVie, Merck Sharp and Dohme, and Roche., 2, Amgen, 5, 8, Bristol-Myers Squibb, 8, Bristol-Myers Squibb, Celgene, Merck Sharp and Dohme, and UCB, 8, Celgene, 5, 8, Janssen, 5, Lilly, 5, 8, Medac, 5, 8, Merck, 5, 8, Merck Sharp and Dohme, 2, 8, Novartis, 2, 5, 8, Pfizer, 5, 8, Roche, 2, 5, 8, Sandoz, 5, 8, Sanofi/Genzyme, 5, 8, UCB, 8; G. Burmester, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma., 5, 8, AbbVie Inc., 5, 8, BMS, 5, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Gilead, 5, 8, Gilead Sciences, Inc., 5, 8, Janssen, 5, 8, Lilly, 5, 8, Merck, 5, 8, Merck Shar & Dohme, 5, 8, MSD, 5, 8, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Roche, Sanofi-Genzyme, 5, 8, Sanofi, 5, 8, UCB, 5, 8, Union Chimique Belge, 2, 5, 8; K. Ford, Sanofi, 1, 3, 4; H. van Hoogstraten, Novartis, 1, Regeneron, 1, Sanofi, 1, 3, Zambon (Dr Falk for PhD research), 2; H. Leher, Regeneron Pharma Inc, 1, 3, 4; K. Thangavelu, EMD Serono, 3, Sanofi, 1, 3, 4; V. Bykerk, AbbVie, 5, Amgen, 1, 2, 3, 5, 8, Brainstorm Therapeutics, 1, 2, 3, 5, 8, Bristol-Myers Squibb, 5, Genentech, 5, Gilead, 5, NIH, 2, Pfizer, 1, 2, 3, 5, 8, Regeneron, 5, Regeneron Pharmaceuticals, Inc, 5, Sanofi, 5, Sanofi/Genzyme-Regeneron, 5, Sanofi-Genzyme/Regeneron, 1, 2, 3, 5, 8, Scipher, 1, 2, 3, 5, 8, The Cedar Hill Foundation, 9, UCB, 1, 2, 3, 5, 8, UCB Pharma, 5.

To cite this abstract in AMA style:

Curtis J, Aletaha D, Burmester G, Ford K, van Hoogstraten H, Leher H, Thangavelu K, Bykerk V. Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/low-probability-of-clinical-worsening-following-switching-biologic-dmard-in-patients-with-ra-and-partial-response-to-adalimumab/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-probability-of-clinical-worsening-following-switching-biologic-dmard-in-patients-with-ra-and-partial-response-to-adalimumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology